Flamingo AI appoints new CTO

|

Published 12-SEP-2018 12:47 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Flamingo AI Limited (ASX:FGO) has announced the appointment of Tony Coorey as its incoming Chief Technology Officer.

The appointment will ensure a smooth transition from outgoing CTO Joe Walker, who will move into a Board Advisory role for the artificial intelligence company.

“I am very happy to have led the development of Flamingo AI’s technology platform, technology team and machine learning capabilities over the past three years.

“We have a world class product and platform. I am thrilled to be handing over to somebody as capable as Mr Coorey who will bring valuable experience to the company.”

FGO founder and CEO Catriona Wallace thanked Walker for his service, “Under Joe’s leadership of the technology team we have built a product and platform that is being used by some of the world’s leading brands and largest companies.

“We are extremely pleased that someone with Tony’s expertise is now joining the Company to support the Company’s next growth phase focused on the commercialisation of the platform,” she said.

It should be noted however that this remains a speculative stock and investors should seek professional financial advice if considering this stock for your portfolio.

Coorey has previously served as CTO at Elsevier Science Publishing, a division of Elsevier (RENX:NYSE) and GraysOnline, subsequently acquired by Eclipx (ASX:ECX).

Source: cio.com.au

He worked closely with FGO’s Commercial Officer Mark Kehoe at Eclipx and will be tasked with progressing the commercialisation and scalability of its existing AI tech.

The incoming CTO was a key technology consultant at Tom Waterhouse from 2011-2014 and was a senior consultant at notable investment firm, Allegro Funds.

In addition, Coorey will play a key role in solidifying FGO’s future strategic direction and partnerships.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X